InvestorsHub Logo
Followers 58
Posts 3961
Boards Moderated 0
Alias Born 04/23/2013

Re: None

Sunday, 04/23/2023 8:24:29 AM

Sunday, April 23, 2023 8:24:29 AM

Post# of 426487
$AMRN Icosapent ethyl demonstrated significant benefits in coronary physiology. This early and sustained improvement in FRCT at 9- and 18-month follow-up provides mechanistic insight into the clinical benefit observed in the REDUCE-IT trial. Furthermore, this is the first assessment of FFRCT to determine drug effect.

It’s the EPA Stupid!

https://doi.org/10.1093/ehjci/jead063
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News